Drug intelligence / Profile preview

SA-002

Development stage: Preclinical
Lead developer: Sanopeutics

Overview

SA-002 is an early-stage drug candidate currently under development by Sanopeutics. It is being investigated for the treatment of unspecified metabolic disorders. As of early 2024, the program is in the preclinical discovery or screening phase. Due to limited public disclosure by the developer, specific details regarding its molecular target, modality (such as small molecule or biologic), and exact mechanism of action have not yet been released.

Targets

DLL3 (Delta-like ligand 3)

Beyond the preview

Go deeper on SA-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SA-002.

Explore the full profile